IRIS Accounts Production v24.2.0.383 04049939 Board of Directors 1.7.23 30.6.24 30.6.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh040499392023-06-30040499392024-06-30040499392023-07-012024-06-30040499392022-06-30040499392022-07-012023-06-30040499392023-06-3004049939ns15:EnglandWales2023-07-012024-06-3004049939ns14:PoundSterling2023-07-012024-06-3004049939ns10:Director12023-07-012024-06-3004049939ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3004049939ns10:SmallEntities2023-07-012024-06-3004049939ns10:AuditExempt-NoAccountantsReport2023-07-012024-06-3004049939ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3004049939ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3004049939ns10:FullAccounts2023-07-012024-06-300404993912023-07-012024-06-3004049939ns10:Director22023-07-012024-06-3004049939ns10:CompanySecretary12023-07-012024-06-3004049939ns10:RegisteredOffice2023-07-012024-06-3004049939ns5:CurrentFinancialInstruments2024-06-3004049939ns5:CurrentFinancialInstruments2023-06-3004049939ns5:ShareCapital2024-06-3004049939ns5:ShareCapital2023-06-3004049939ns5:RetainedEarningsAccumulatedLosses2024-06-3004049939ns5:RetainedEarningsAccumulatedLosses2023-06-3004049939ns5:IntangibleAssetsOtherThanGoodwill2023-07-012024-06-3004049939ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-07-012024-06-3004049939ns5:LeaseholdImprovements2023-07-012024-06-3004049939ns5:MotorVehicles2023-07-012024-06-3004049939ns5:ComputerEquipment2023-07-012024-06-3004049939ns5:IntangibleAssetsOtherThanGoodwill2023-06-3004049939ns5:IntangibleAssetsOtherThanGoodwill2024-06-3004049939ns5:IntangibleAssetsOtherThanGoodwill2023-06-3004049939ns5:LeaseholdImprovements2023-06-3004049939ns5:PlantMachinery2023-06-3004049939ns5:MotorVehicles2023-06-3004049939ns5:ComputerEquipment2023-06-3004049939ns5:PlantMachinery2023-07-012024-06-3004049939ns5:LeaseholdImprovements2024-06-3004049939ns5:PlantMachinery2024-06-3004049939ns5:MotorVehicles2024-06-3004049939ns5:ComputerEquipment2024-06-3004049939ns5:LeaseholdImprovements2023-06-3004049939ns5:PlantMachinery2023-06-3004049939ns5:MotorVehicles2023-06-3004049939ns5:ComputerEquipment2023-06-3004049939ns5:CostValuation2023-06-3004049939ns5:AdditionsToInvestments2024-06-3004049939ns5:CostValuation2024-06-3004049939ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-3004049939ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-30
REGISTERED NUMBER: 04049939 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 June 2024

for

Biomax Limited

Biomax Limited (Registered number: 04049939)

Contents of the Financial Statements
for the Year Ended 30 June 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Biomax Limited

Company Information
for the Year Ended 30 June 2024







DIRECTORS: Mr R P Smith
Mrs J M Shambrook





SECRETARY: Mrs J M Shambrook





REGISTERED OFFICE: Beck Cottage
Main Street
Elvington
York
YO41 4AG





REGISTERED NUMBER: 04049939 (England and Wales)





ACCOUNTANTS: Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Biomax Limited (Registered number: 04049939)

Balance Sheet
30 June 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 10,537 10,537
Tangible assets 5 146,669 100,610
Investments 6 696,874 395,285
854,080 506,432

CURRENT ASSETS
Stocks 116,672 106,694
Debtors 7 885,125 872,276
Cash at bank 518,558 702,487
1,520,355 1,681,457
CREDITORS
Amounts falling due within one year 8 198,331 201,534
NET CURRENT ASSETS 1,322,024 1,479,923
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,176,104

1,986,355

PROVISIONS FOR LIABILITIES 13,830 2,316
NET ASSETS 2,162,274 1,984,039

CAPITAL AND RESERVES
Called up share capital 2 2
Retained earnings 2,162,272 1,984,037
SHAREHOLDERS' FUNDS 2,162,274 1,984,039

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Biomax Limited (Registered number: 04049939)

Balance Sheet - continued
30 June 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 3 September 2024 and were signed on its behalf by:





Mrs J M Shambrook - Director


Biomax Limited (Registered number: 04049939)

Notes to the Financial Statements
for the Year Ended 30 June 2024


1. STATUTORY INFORMATION

Biomax Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

Turnover
Revenue is measured at the fair value of the consideration received or receivable and represents the amount receivable for goods supplied or services rendered, net of returns, discounts and rebates allowed by the company and value added taxes.

The company recognises revenue when the significant risks and rewards of ownership have been transferred to the buyer; the company retains no continuing involvement or control over the goods; the amount of revenue can be measured reliably; it is probable that future economic benefits will flow to the entity and when the specific criteria relating to each of the company's sales channels have been met.

The company supplies natural animal and human food ingredients to other organisations.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development Costs are being amortised evenly over their estimated useful life of nil years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - Not depreciated
Motor vehicles - 25% on reducing balance
Computer equipment - 33% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors are initially recognised at transaction value and subsequently measure at their settlement value.

Biomax Limited (Registered number: 04049939)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024


2. ACCOUNTING POLICIES - continued

Research and development
Expenditure on research and development is capitalised to the extent that it is considered to have ongoing value by the directors

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 4 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 July 2023
and 30 June 2024 10,537
NET BOOK VALUE
At 30 June 2024 10,537
At 30 June 2023 10,537

5. TANGIBLE FIXED ASSETS
Improvements
to Plant and Motor Computer
property machinery vehicles equipment Totals
£    £    £    £    £   
COST
At 1 July 2023 91,348 2,437 34,996 16,534 145,315
Additions - 3,100 50,170 3,030 56,300
Disposals - - (34,996 ) - (34,996 )
At 30 June 2024 91,348 5,537 50,170 19,564 166,619
DEPRECIATION
At 1 July 2023 - 2,221 30,325 12,159 44,705
Charge for year - 846 1,045 3,679 5,570
Eliminated on disposal - - (30,325 ) - (30,325 )
At 30 June 2024 - 3,067 1,045 15,838 19,950
NET BOOK VALUE
At 30 June 2024 91,348 2,470 49,125 3,726 146,669
At 30 June 2023 91,348 216 4,671 4,375 100,610

Biomax Limited (Registered number: 04049939)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024


6. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
At 1 July 2023 395,285
Additions 301,589
At 30 June 2024 696,874
NET BOOK VALUE
At 30 June 2024 696,874
At 30 June 2023 395,285

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 93,683 97,112
Other debtors 791,442 775,164
885,125 872,276

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 66,528 72,696
Taxation and social security 128,053 124,502
Other creditors 3,750 4,336
198,331 201,534

9. RELATED PARTY DISCLOSURES

Included in other debtors is an inter-company balance of £769,801 (2023: £769,201) owed by Maryhill Limited, a company owned and controlled by both directors.